Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
2027. jan. 15.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
FLT3-ITD Targeted Therapy in Fit AML Patients
2026. dec. 1.· PHASE2_PHASE3 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
2026. nov. 11.· PHASE1_PHASE2 · RECRUITING· CTGOV
Publikáció
Performance Evaluation and Validation of a Next-Generation Sequencing-Based Measurable Residual Disease Assay for FLT3 Internal Tandem Duplication Detection in Acute Myeloid Leukemia.
2026. nov. 6.· Annals of laboratory medicine· PUBMED
Publikáció
Frequent FLT3 and IDH co-mutations in acute myeloid leukemia with mutated NPM1, NUP98 rearrangement, and KMT2A partial tandem duplication but not rearrangement: potential for combined targeted therapy.
2026. nov. 5.· Haematologica· PUBMED
Publikáció
Synthesis, in silico studies, and in vitro evaluation of novel isoindigo inhibitors targeting wild-type and D835Y mutant FLT3.
2026. nov. 3.· RSC advances· PUBMED
Vizsgálat
MAC vs RIC for Transplantation in FLT3-ITD-Mutated AML Guided by UHS-NGS MRD ( FLT3 - MAC vs RIC )
2026. nov. 1.· NA · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis
2026. nov. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Prognostic Impact of FLT3-ITD Microclones in AML: An EHA AML-Specialized Working Group Study.
2026. nov. 1.· American journal of hematology· PUBMED
Publikáció
Clinical and molecular characteristics of FLT3-ITD microclones in elderly patients with acute myeloid leukemia receiving less-intensive therapy.
2026. okt. 30.· Leukemia· PUBMED
Publikáció
Quizartinib in older patients (aged ≥60 years) with newly diagnosed FLT3-ITDpositive acute myeloid leukemia: subgroup analyses from QuANTUM-First.
2026. okt. 29.· Haematologica· PUBMED
Publikáció
Prognostic Impact of FLT3-ITD Allelic Ratio in AML Patients Treated With High-Dose Anthracycline and a FLT3 Inhibitor.
2026. okt. 26.· American journal of hematology· PUBMED
Publikáció
Patient-tailored azacitidine, venetoclax and gilteritinib triplet therapy appear to improve tolerability while preserving encouraging clinical outcomes in FLT3-mutated relapsed/refractory AML.
2026. okt. 23.· Annals of hematology· PUBMED
Publikáció
Targeting the mitochondrial complex I subunit NDUFS2 potentiates FLT3 inhibition in acute myeloid leukaemia with FLT3 internal tandem duplication.
2026. okt. 19.· Leukemia· PUBMED
Publikáció
Focus on Azole-Based and Other N-Containing Heterocycles Within the Landscape of Current Structural Classes as Feline McDonough Sarcoma-Like Tyrosine Kinase 3 (FLT3) Inhibitors for Acute Myeloid Leukemia.
2026. okt. 19.· Medicinal research reviews· PUBMED
Publikáció
XY0206: A promising sunitinib-derived FLT3 inhibitor targeting therapy-resistant acute myeloid leukemia.
2026. okt. 15.· The Journal of clinical investigation· PUBMED
Publikáció
Successful Salvage Therapy With Quizartinib Plus Chemotherapy Followed by Quizartinib Monotherapy for Transplant Bridging and Post-Transplant Maintenance in a Child With Induction-Refractory FLT3-ITD-Positive AML.
2026. okt. 15.· Pediatric blood & cancer· PUBMED
Publikáció
Regional practice differences significantly affect the benefit of post-HCT gilteritinib in FLT3-ITD AML.
2026. okt. 13.· Blood advances· PUBMED
Publikáció
Genomic Determinants of Induction Failure and Persistent Prognostic Risk of FLT3-ITD in Pediatric Acute Myeloid Leukemia.
2026. okt. 12.· Cancers· PUBMED
Publikáció
Structure-Based Optimization of 2-Aminopyrimidine Derivatives as Potent Multi-target FLT3/CHK1/IRAK4 Inhibitors for Acute Myeloid Leukemia.
2026. okt. 8.· Journal of medicinal chemistry· PUBMED
Publikáció
HPMES: an ultra-sensitive mutation enrichment strategy for FLT3-ITD MRD monitoring in acute myeloid leukemia.
2026. okt. 7.· Biosensors & bioelectronics· PUBMED
Publikáció
FLT3-Mutated AML: Transplanting with Precision in the Targeted Era.
2026. okt. 1.· Current hematologic malignancy reports· PUBMED
Publikáció
Efficacy of Sorafenib Combined with Venetoclax and Azacitidine in Newly Diagnosed FLT3-ITD-Mutant Acute Myeloid Leukemia: Remission Efficacy and Prognostic Influence of Post-Remission Consolidation Therapy.
2026. szept. 29.· Journal of clinical medicine· PUBMED
Publikáció
Novel juxtamembrane FLT3 in-frame insertion in a child with refractory AML: a case report of durable remission following allogeneic HSCT and FLT3 inhibitor therapy.
2026. szept. 25.· Frontiers in oncology· PUBMED
Publikáció
Sorafenib enhances graft-versus-leukemia activity through IL-18-mediated macrophage and NK cell crosstalk in FLT3-ITD acute myeloid leukemia.
2026. szept. 22.· Cell reports· PUBMED
Publikáció
Chromosomal Heterogeneity and Enrichment of Mitotic Regulatory Programs Reveal a Therapeutic Vulnerability in Cytarabine-Resistant FLT3-ITD AML.
2026. szept. 21.· Current issues in molecular biology· PUBMED
Publikáció
FLT3 inhibitor maintenance after allogeneic transplantation is associated with improved survival in FLT3-mutated AML: MRD-stratified evidence from an updated meta-analysis.
2026. szept. 21.· Bone marrow transplantation· PUBMED
Publikáció
Design, synthesis and biological evaluation of a series of new, potent FLT3 PROTAC degraders with rigid linkers.
2026. szept. 19.· Bioorganic & medicinal chemistry· PUBMED
Publikáció
RAS seals fate in AML besieged by FLT3 and BCL2 inhibitors.
2026. szept. 17.· Blood· PUBMED
Publikáció
Dynamic genetic and nongenetic RAS-pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.
2026. szept. 17.· Blood· PUBMED